Exchange: NASDAQ·Updated 07:30 PM EST
ANAB logo

ANAB AnaptysBio Inc

$46.63
$0.77
(1.62%)
Today
Closed $46.63
$0.00
(0.00%)
After Hours
EarningsMar 3
Mkt Cap$1.39B
Vol432,450.00

About ANAB

AnaptysBio, Inc. is a clinical-stage biotechnology company, which engages in delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The firm’s product pipeline includes Rosnilimab, ANB033, ANB101, Jemperli, and Imsidolimab. It operates through the Biopharma and Royalty Management segments. The Biopharma segment focuses on the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases. The Royalty Management segment manages the financial collaboration for Jemperli with GSK and for imsidolimab with Vanda. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
40

Bearish Sentiment

How do you feel about ANAB?

BiotechSwings
everyone is watching Vanda into Dec 12 and $ANAB is sitting right there with a 10% royalty on Quimilza 27 days out. imsidolimab for generalized pustular psoriasis, IL 36 receptor blocker, pivotal data in NEJM Evidence, closed Friday at 46.25 imo
1
BiotechSwings
nobody is pricing the 10% royalty angle on $ANAB yet imo. 22 days out, Dec 12 Quimilza decision in GPP, GEMINI did 53% clear vs 13% on placebo
StockBraker
$ANAB Investment Strategy: EcoR1 targets companies developing novel therapeutics for high-unmet-need diseases. The firm takes a concentrated, high-conviction approach—frequently taking large ownership stakes (often filing 13D/13G activist or passive major-shareholder disclosures) and actively advising management teams on clinical development, financing, and corporate strategy.
shoc24
$ANAB reported earnings after the close today. GAAP EPS beat estimates: $0.11 vs. -$1.84 expected, according to Stock Meadow.
StockBraker
$ANAB We are all patiently awaiting a decision 🤞🏻 AnaptysBio, Inc. and TESARO, Inc. (a subsidiary of GSK plc) are engaged in a high-stakes legal dispute in the Delaware Court of Chancery. A court decision is expected in the fourth quarter of 2026 or the first quarter of 2027.

Advertisement|Remove ads.